Ab­b­Vie hus­tles its uni­corn drug Ro­va-T in­to the clin­ic in com­bo with Bris­tol's Op­di­vo

Ab­b­Vie is wast­ing lit­tle time in get­ting its new­ly ac­quired drug Ro­va-T in­to the clin­ic for small cell lung can­cer in com­bi­na­tion with a check­point ther­a­py. And its can­cer team is go­ing with the mar­ket leader, Bris­tol-My­ers Squibb, and its megablock­buster Op­di­vo as well as Yer­voy.

Gary Gor­don, the vice pres­i­dent for on­col­o­gy at Ab­b­Vie, told me at AS­CO re­cent­ly that he was work­ing on an I/O com­bo pact, part of Ab­b­Vie’s am­bi­tious plans to piv­ot in­to reg­is­tra­tion stud­ies that would po­si­tion the com­pa­ny for a pos­si­ble near-term ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.